Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR   US00484M1062

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/12/2014 12/15/2014 12/16/2014 12/17/2014 12/18/2014 Date
38.7(c) 38.4(c) 38.25(c) 38.47(c) 40.35 Last
324 019 669 463 462 104 640 721 518 250 Volume
+0.16% -0.78% -0.39% +0.58% +4.89% Change
More quotes
Company
Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system.The company's two main products are Ampyra and Zanaflex... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 386 M
EBIT 2014 43,2 M
Net income 2014 20,1 M
Debt 2014 205 M
Yield 2014 -
Sales 2015 413 M
EBIT 2015 23,1 M
Net income 2015 6,36 M
Debt 2015 153 M
Yield 2015 -
PER 2014 81,85
PER 2015 159,43
EV / Sales 2014 4,72x
EV / Sales 2015 4,28x
Capitalization 1 614 M
More Financials
Latest news on ACORDA THERAPEUTICS INC
16h ago ACORDA THERAPEUTICS : Commences Phase 3 Clinical Trial for Dalfampridine
3d ago ACORDA THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
3d ago ACORDA THERAPEUTICS : Announces Initiation of Phase 3 Clinical Trial for Dalfamp..
12/11 ACORDA THERAPEUTICS : Assigned Patent
12/10 ACORDA THERAPEUTICS : to Present at the 26th Annual Piper Jaffray Healthcare Con..
12/10 ACORDA THERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)
12/10 ACORDA THERAPEUTICS : Announces Initiation of Phase 3 Trial of CVT-301 in Parkin..
12/02 ACORDA THERAPEUTICS : to Present at the 26th Annual Piper Jaffray Healthcare Con..
More news
Sector news
10h ago ALNYLAM PHARMACEUTICALS : Elects Michael W. Bonney to Its Board of Directors
1d ago MEDIVATION : Announces Participation at Upcoming Investor Conference
1d ago QUINTILES TRANSNATIONAL : CEO Tom Pike to Present at J.P. Morgan Healthcare Conf..
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF